Aspirin administration for primary prevention in patients with chronic kidney disease did not significantly reduce the risk of major adverse cardiovascular events when pooling randomized and observational evidence (HR 0.97).
Meta-Analysis (n=24,352)
Does aspirin reduce cardiovascular events in patients with chronic kidney disease for primary prevention?
Aspirin for primary prevention in CKD patients may reduce cardiovascular events based on RCTs but increases major bleeding, with overall mixed evidence when including observational data.
Effect estimate: HR 0.97 (95% CI 0.75-1.25)
AIM: Chronic kidney disease is associated with increased risk of cardiovascular diseases (CVD). This meta-analysis aims to evaluate the efficacy and safety of aspirin administered for primary prevention of CVD in patients with chronic kidney disease. METHODS: PubMed, Scopus, Web of Science, CENTRAL and Clinicaltrials.gov were systematically searched from inception to 22 June 2023. Randomized controlled trials (RCTs) and cohort studies evaluating aspirin as primary prevention of CVD in chronic kidney disease were included. Meta-analysis was conducted using random-effects models. RESULTS: Overall, 11 studies (6 RCTs and 5 cohort studies) with 24,352 patients were included. The meta-analysis of RCTs indicated that aspirin was associated with lower risk of major adverse cardiovascular events hazard ratio (HR): 0.79; 95% confidence intervals (CI): 0.64-0.97 and higher risk of major bleeding risk ratio (RR): 1.35; 95% CI 1.15-1.58. Incorporating observational evidence led to statistically non-significant findings in terms of risk of both cardiovascular events (pooled HR: 0.97; 95% CI 0.75-1.25; low certainty) and major bleeding (pooled RR: 1.21; 95% CI 0.99-1.48; moderate certainty). No statistically significant differences between aspirin and placebo were observed in the outcomes of mortality, coronary heart disease, stroke and renal events. CONCLUSIONS: RCT evidence points to a possible benefit in cardiovascular event reduction from aspirin administration, at the cost of increased major bleeding risk. This finding was not confirmed when the existing observational evidence was incorporated. Further research should determine the most appropriate subpopulation of chronic kidney disease patients that would benefit the most from prophylactic aspirin therapy. REGISTRATION: The study protocol has been prospectively registered and is publicly available from: https://doi.org/10.17504/protocols.io.261ged63jv47/v1 .
Bellos et al. (Thu,) conducted a meta-analysis in Chronic kidney disease (n=24,352). Aspirin vs. Placebo was evaluated on Major adverse cardiovascular events (MACE) (HR 0.97, 95% CI 0.75-1.25). Aspirin administration for primary prevention in patients with chronic kidney disease did not significantly reduce the risk of major adverse cardiovascular events when pooling randomized and observational evidence (HR 0.97).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: